TABLE 4.
Inhibition of VEGF-A165 binding to VEGFR1 and VEGFR2 by VEGF dual dAb and aflibercept
Data are the mean from n = 3 experiments, except bevacizumab (R1, n = 3; R2, n = 11) and ranibizumab (R2, n = 2) determined by MSD (numbers in parentheses represent S.D.).
| Molecule | VEGFR1 IC50 | VEGFR2 IC50 | 
|---|---|---|
| pm | pm | |
| Aflibercept | 75 (10.2) | 32 (3.5) | 
| VEGF dual dAb | 59 (11.8) | 22 (2.7) | 
| Bevacizumab | 2204 (82.0) | 2661 (1279) | 
| Ranibizumab | NDa | 1166 (124.9) | 
a ND, not determined.